FDA Brief

Warning letters Drugs

FDA warning letter to

UCSF Radiopharmaceutical Facility

High riskIssued Apr 13Posted Apr 21Center for Drug Evaluation and Research (CDER)

FDA cited UCSF Radiopharmaceutical Facility for inadequate sterility failure investigations and environmental monitoring of sterile drug manufacturing.

What happened

FDA inspected the facility from July 21 to 24, 2025, and reviewed the company’s August 14, 2025 response. FDA found inadequate investigations into multiple sterility test failures from 2022 to 2023, including invalidating positive results without compelling evidence of laboratory contamination and without adequately evaluating manufacturing causes. FDA also found that adverse environmental monitoring trends were not investigated and some investigations stayed open for more than 1,000 days.

What FDA found

  1. The company did not adequately investigate repeated sterility test failures or take appropriate corrective action, and it invalidated positive results without compelling evidence that lab contamination caused them.

    21 CFR (b)(4)
  2. The company did not follow its own quality procedures: it failed to investigate adverse environmental monitoring trends and left numerous investigations open for more than a year, including two for over 1,000 days.

    21 CFR (b)(4)
  3. The company’s equipment and environmental monitoring procedures were inadequate: contact plates were taken right after disinfection, which can cause false negatives, and the critical ISO 5 area was not monitored.

    21 CFR (b)(4)
  4. The company did not submit required Field Alert Reports to FDA within three working days after discovering product quality defects or bacteriological contamination.

    21 C.F.R. 314.81(b)(1)(ii); section 505(k) of the FD&C Act [21 U.S.C. 355(k)]

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with comprehensive corrective action plans, including independent reviews of invalidated sterility tests and environmental monitoring, quality unit remediation, and cleaning/disinfection improvements.

Who should pay attention

  • other sterile injectable and radiopharmaceutical manufacturers
  • hospital pharmacies and clinics that administer these drugs
  • quality teams responsible for aseptic processing and environmental monitoring

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. NexCell Scientific Inc

    NexCell Scientific markets an unapproved, unlicensed umbilical cord blood cell product with serious manufacturing violations.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. R3 Medical Companies

    FDA cites R3 Medical affiliates for selling unapproved umbilical cord and exosome biologics without licenses and with serious manufacturing violations.

    High risk